Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin/pramlintide - Adocia

Next Previous
Drug Profile

Insulin/pramlintide - Adocia

Alternative Names: ADO09; BC AsPram; BC Lis Pram; BC Pram Ins; BioChaperone Lispro Pramlintide; BioChaperone Pramlintide hIns; BioChaperone® AsPram; BioChaperone® Insulin Pramlintide; BioChaperone® LisPram; BioChaperone® Pramlintide Insulin; Insulin Lispro/pramlintide - Adocia; M1 pram - ADO09; M1pram; P037; Pramlintide/A21G human insulin; Pramlintide/insulin-lispro

Latest Information Update: 28 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adocia
  • Developer Adocia; McGill University
  • Class Antihyperglycaemics; Insulins; Macromolecular substances; Pancreatic hormones; Proteins
  • Mechanism of Action Islet amyloid polypeptide stimulants; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Obesity; Type 1 diabetes mellitus
  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 28 Aug 2024 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in Canada (SC, Injection)
  • 14 May 2024 Adocia plans a phase IIb trial in Type 1 diabetes in the US in third quarter of 2024
  • 28 Feb 2024 Adocia plans a phase III trial for Type 1 diabetes mellitus in the US (SC) in the third quarter of 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top